Botanix Announces Landmark Descheduling of Synthetic CBD by the DEA

Botanix Pharma's partner in the US, Purisys, has received confirmation from the DEA that synthetic CBD has been officially removed from Schedule 1 of the Controlled Substances Act. There was monumental news today from the Australian clinical stage synthetic cannabinoid developer, Botanix Pharmaceuticals Limited (ASX: BOT), after the company announced that its US-based partner, Purisys, … Continue reading Botanix Announces Landmark Descheduling of Synthetic CBD by the DEA